APPENDIX 4C – 30 JUNE 2026

QUARTERLY ACTIVITIES & CASHFLOW REPORT

Highlights:

- *Advanced preparations for a late-stage trial in moderate to severe acute ischaemic stroke (AIS) patients. A global stroke Clinical Advisory Committee convened, where international experts gathered to review and optimise the upcoming clinical trial design. The trial will leverage a precision medicine strategy to facilitate clinical trial enrolment and increase probability of success.*

- *Three FDA-requested assays (hERG, TNK and genotox) completed, all demonstrating clean and favourable safety profiles. Following finalisation of the late-stage trial protocol in the coming weeks, Argenica will be well positioned to submit a comprehensive response to the FDA clinical hold and seek approval of the IND for ARG-007 (xaranetide), a pivotal step toward commencing a clinical trial in the US.*

- *World Health Organisation confirmed the International Nonproprietary Name, xaranetide, for the Company's lead neuroprotective drug candidate, ARG-007.*

- *Xaranetide demonstrated significant neuroprotection in a preclinical concussion study, adding to a growing body of evidence across mild, moderate, and severe TBI injury models. Considering next steps to advance xaranetide's development in this indication.*

- *Growing clinical and scientific engagement with two abstracts from the Phase 2 clinical trial of ARG-007 (xaranetide) presented at the European Stroke Organisation Conference and attendance at BIO 2026 in San Diego.*

- *With cash reserves of $6.35 million at 30 June 2026, Argenica is well-funded to continue to advance preparatory activities for a targeted late-stage clinical AIS trial.*

Perth, Australia; 24 JULY 2026 – Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury, is pleased to lodge the following quarterly update and attached Appendix 4C Quarterly Cashflow Report for the period ended 30 June 2026.

Argenica completed a Phase 2 clinical trial of ARG-007 (xaranetide) in acute ischaemic stroke (AIS) patients conducted across Australian hospitals during 2025. This proof-of-concept clinical trial provided data on the safety and efficacy of ARG-007 in AIS patients presenting to emergency departments across Australia. On the strength of the trial safety and functional efficacy data, as well as the efficacy signal seen in more severe stroke patients as evidenced by work conducted by AI Company Brainomix, Argenica is designing and advancing a targeted late-stage AIS trial in consultation with its global stroke Clinical Advisory Committee and potential pharmaceutical partners.

In June 2025, the Company was awarded up to $1.5 million in non-dilutive funding under the Australian Government's Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator ("TTRA") program for Diabetes and Cardiovascular Disease, delivered by MTPConnect, which supports activities to establish this late-stage clinical trial.

In parallel, the Company has projects investigating the potential utility of ARG-007 (xaranetide) in other neurological conditions. Underpinning this research, over $4 million in non-dilutive grant and philanthropic funding has been secured throughout the life of the projects from the Federal and Western Australian governments, the Stan Perron Charitable Foundation, the McCusker Foundation, and donors to the Perron Institute.

Key activities undertaken during the quarter are outlined below:

PREPARATORY ACTIVITIES FOR A LATE-STAGE TRIAL ADVANCED, SUPPORTED BY STRENGTH OF THE PHASE 2 TRIAL SAFETY AND FUNCTIONAL EFFICACY DATA

During the quarter, Argenica progressed key preparatory activities for a late-stage clinical trial in moderate to severe AIS, building on the safety and efficacy outcomes observed in this patient group in the Phase 2 trial.

Drug substance manufacturing is advancing with Corden Pharma (Europe), which is developing the scaled manufacturing process for ARG-007 to support clinical trials and future commercial supply. This represents an important step in de-risking the program and ensuring readiness for a late-stage trial.

Argenica is working closely with leading global experts in stroke clinical trials and biostatistics to finalise the protocol design for this trial. The trial will be designed as either a Phase 2b or a seamless Phase 2b/3 trial aimed at optimising patient selection by focusing on stroke severity and leveraging AI-enabled diagnostic tools to assist clinicians in identifying and enrolling those patients most likely to benefit, thereby increasing the probability of clinical success and enhancing the overall efficiency of the development program.

The clinical trial design and strategy will be presented to the market in Q3 CY2026.

Following the decision on the protocol for the late-stage trial, the Company will complete the protocol synopsis for submission to the U.S. Food and Drug Administration (FDA) for feedback, which is expected prior to the end of Q3 CY2026. This interaction is a key milestone in aligning the late-stage trial design with regulatory expectations.

These activities position Argenica to advance ARG-007 into the next stage of clinical development, with a focus on delivering a robust, well-designed trial.

THREE FDA-REQUESTED ASSAYS (HERG, TNK AND GENOTOX) COMPLETED, ALL DEMONSTRATING CLEAN AND FAVOURABLE SAFETY PROFILES

As previously disclosed to the market, Argenica received an IND clinical hold letter from the US Food and Drug Administration (FDA) in relation to ARG-007 (xaranetide). The FDA's letter highlighted additional data relating to ARG-007's interaction with the clot-dissolving drug tenecteplase (TNK), its potential impact on cardiac activity, assessed using a hERG assay and its genotoxicity. In relation to genotoxicity, the FDA requested a follow-up in vitro mammalian cell gene mutation assay, such as the mouse lymphoma thymidine kinase (TK) assay, to be conducted.

During the quarter, Argenica finalised completion of the requested assays, with all three demonstrating clean and favourable safety profiles.

Following finalisation of the trial protocol in the coming weeks, Argenica will be well positioned to submit a comprehensive response to the FDA clinical hold and seek approval of the IND for ARG-007 (xaranetide), a pivotal step toward commencing the late-stage clinical trial in acute ischaemic stroke patients in the US.

WORLD HEALTH ORGANISATION CONFIRMS INTERNATIONAL NONPROPRIETARY NAME FOR ARG-007

During the quarter, the World Health Organisation (WHO) confirmed the International Nonproprietary Name (INN) xaranetide ("za-RAN-e-tide") for the Company's lead neuroprotective drug candidate, ARG-007, with no objections noted. Xaranetide will become the recognised generic name for ARG-007 across regulatory, scientific and medical communities globally. The Company will now begin to include xaranetide in communications.

ARG-007 (XARANETIDE) SHOWS SIGNIFICANT NEUROPROTECTION IN PRECLINICAL CONCUSSION STUDY

After quarter end, Argenica was pleased to report results from a pre-clinical concussion study. Xaranetide showed significant efficacy in reducing the secondary injury effects in a repeated mild traumatic brain injury (mTBI), or concussion, preclinical animal model. Xaranetide demonstrated broad neuroprotective activity by attenuating multiple pathological processes

implicated in concussion, including neuroinflammation (reduced astrocyte and microglial activation), oxidative stress, and axonal injury.

The preclinical study, undertaken by Curtin University, showed a single low-dose of xaranetide (1 mg/kg IV) administered 30 minutes after a repeated mTBI significantly reduced neuroinflammation, oxidative stress and axonal damage, three of the most significant components of the secondary injury cascade seen following concussion. Importantly, this effect was enduring, lasting up to 11 days post-injury.

Xaranetide significantly reduced neuroinflammation — driven by overactive immune cells (astrocytes and microglia) — across multiple brain regions involved in memory and cognition (hippocampus, cortex, corpus callosum). It also lowered markers of cellular damage (oxidative stress) and reversed structural damage to nerve fibers in the ventral tegmental area (VTA), a region tied to mood and motivation.

These findings suggest xaranetide may not simply alleviate symptoms but may modify the underlying biological response to concussion. Importantly, these findings are consistent with previously reported efficacy in multiple moderate and severe traumatic brain injury models, demonstrating biological activity across the spectrum of traumatic brain injury severity, increasing confidence that xaranetide is targeting fundamental pathways of brain injury.

Based on these results, Argenica is now considering next steps to advance xaranetide's development in this indication.

Refer to ASX Announcement “ARG-007 (Xaranetide) Shows Significant Neuroprotection in Preclinical Concussion Study” released on 16 July 2026 for further details.

GROWING CLINICAL AND SCIENTIFIC ENGAGEMENT AT ESOC AND BIO 2026

During the quarter, two abstracts from the Phase 2 clinical trial of ARG-007 (xaranetide) were presented at the European Stroke Organisation Conference (ESOC), a leading global forum for stroke research and clinical advancement, held in the Netherlands, showcasing the safety profile and functional efficacy outcomes of ARG-007 to an international audience of clinicians, researchers and key opinion leaders. Argenica also attended BIO 2026 in San Diego, the world's largest biotechnology and life sciences event.

These conferences and presentations provided an important opportunity to increase visibility of the program, validate the clinical data within the global stroke community, and support ongoing engagement with potential partners and investigators ahead of the planned late-stage AIS trial.

CASHFLOW COMMENTARY, CASH RESERVES OF $6.35 MILLION AS AT 30 JUNE 2026

The Company is well funded to continue to advance preparatory activities for a targeted late-stage clinical AIS trial in consultation with its global stroke Clinical Advisory Committee and potential pharmaceutical partners, with cash reserves of $6.35 million as at 30 June 2026.

The Company had net operating cash outflows of $1.605 million for the quarter ended 30 June 2026.

Operating cashflows in the quarter included expenditure on research and development activities of $0.995 million (Mar26Q: $0.992 million), staff costs (including research and development employees) of $0.432 million (Mar26Q: $0.444 million) and corporate administration of $0.199 million (Mar26Q: $0.187 million).

Research and development (R&D) expenditure in the quarter included further investment in drug manufacturing for a late-stage AIS trial, the longest lead item for the trial. R&D expenditure also included payments to third party contractors undertaking pre-clinical and non-clinical studies including TBI and IND enabling studies and regulatory advice.

Argenica is eligible for an R&D tax incentive cash rebate on its FY26 eligible R&D expenditure and has commenced preparation of the required submissions.

As required by ASX Listing Rule 4.7C3, the Company notes that $0.153 million was paid to related parties during the quarter (as noted in section 6 of the attached Appendix 4C) and these payments included salary and superannuation paid to the Executive Director and Directors' fees and superannuation paid to Non-Executive Directors.

This announcement has been approved for release by the Board of Argenica.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company's lead drug candidate, ARG-007 (xaranetide), is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ARGENICA THERAPEUTICS LIMITED	
ABN	**Quarter ended ("current quarter")**
78 637 578 753	30 JUN 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(995)	(6,513)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(432)	(2,014)
	(f) administration and corporate costs	(199)	(848)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	55	241
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives		
	- CRCP grant	-	15
	- TTRA grant	-	857
	- Other grant	-	5
	- R&D tax rebate	-	3,975
1.8	Other (provide details if material)		
	- Net GST (paid) / received	(34)	96
1.9	**Net cash from / (used in) operating activities**	**(1,605)**	**(4,186)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12months) $A'000
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**0**	**0**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(3)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**-**	**(3)**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	7,960	10,544
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,605)	(4,186)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(3)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**6,355**	**6,355**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	813	4,410
5.2	Call deposits	5,550	3,550
5.3	Bank overdrafts	(8)	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**6,355**	**7,960**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	153
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,605)
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,355
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	6,355
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	4.0

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: ....24 JULY 2026.....

Authorised by: ....By the Board of the Company.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.